Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jordi Piro"'
Autor:
Marij J. P. Welters, Dominik Maurer, Ulrik Lassen, Martin Löwer, Bernhard Rossler, Ugur Sahin, Andreas von Deimling, Toni Weinschenk, Christian H. Ottensmeier, Elisa Rusch, Colette Song, Valérie Dutoit, Jordi Rodon, Norbert Hilf, Hans Skovgaard Poulsen, Nina Pawlowski, Francisco Martínez-Ricarte, Judith R. Kroep, Juan Sahuquillo, Claudia Wagner, Edward W. Green, Sonja Dorner, Cedrik M. Britten, Franziska Hoffgaard, Jens Fritsche, Ghazaleh Tabatabai, Stefan Stevanovic, Harpreet Singh-Jasuja, Marco Skardelly, Sabrina Kuttruff-Coqui, Hans-Georg Rammensee, Katharina Kiesel, Alexander Ulges, Carsten Reinhardt, Michael Platten, Alexandra Kemmer-Brück, Bracha Shraibman, Denis Migliorini, Sebastian Kreiter, Jordi Piro, Oliver Schoor, Valesca Bukur, Katrin Frenzel, Berta Ponsati, David Capper, Jorg Ludwig, Monika Stieglbauer, Regina Mendrzyk, Miriam Meyer, Sjoerd H. van der Burg, Evelyna Derhovanessian, Pierre-Yves Dietrich, Arie Admon, Arbel D. Tadmor, Manja Idorn, Wolfgang Wick, Hideho Okada, Per thor Straten, Sandra Heesch, Lukas Bunse, Christoph Huber, Katy J. McCann, Cécile Gouttefangeas, John C. Castle
Publikováno v:
Nature, 565(7738), 240
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Nature, Vol. 565, No 7738 (2019) pp. 240-245
Patients with glioblastoma currently do not sufficiently benefit from recent breakthroughs in cancer treatment that use checkpoint inhibitors1,2. For treatments using checkpoint inhibitors to be successful, a high mutational load and responses to neo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11b11cf9d2f3e8456103640b3a57a625
https://hdl.handle.net/1887/119498
https://hdl.handle.net/1887/119498
Autor:
Ghazaleh Tabatabai, Peter Lewandrowski, Monika Stieglbauer, Stefan Stevanovic, Sandra Heesch, Per thor Straten, Jordi Rodon, Ugur Sahin, Juan Sahuquillo, Colette Song, Valérie Dutoit, Randi Kristina Feist, Christian H. Ottensmeier, Francisco Martínez-Ricarte, Sabrina Kuttruff-Coqui, Hideho Okada, Bernhard Rössler, Judith R. Kroep, Wick Wolfgang, Jens Fritsche, Regina Mendryzk, Norbert Hilf, Karoline Laske, Hans-Georg Rammensee, Carsten Reinhardt, Marij Schoenmaekers-Welters, Harpreet Singh-Jasuja, Stevermann Lea, Toni Weinschenk, Michael Platten, Sjoerd H. van der Burg, Marco Skardelly, Katrin Frenzel, Ulrik Lassen, Christoph Huber, Valesca Bukur, Arie Admon, Berta Ponsati, David Capper, Hans Skovgaard Poulsen, Pierre-Yves Dietrich, Miriam Meyer, Anna Paruzynski, Nina Pawlowski, Sebastian Kreiter, Cécile Gouttefangeas, Andreas von Deimling, Martin Löwer, Jordi Piro
Publikováno v:
Cancer Research. 76:2654-2654
The Glioma Actively Personalized Vaccine Consortium (GAPVAC; funded by the European Union Framework 7 Program) aims at treating newly diagnosed glioblastoma (GB) patients with two distinct actively personalized vaccines (APVACs). Resected tumor mater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89c12cda11f18b33762df595819c6a64
https://doi.org/10.1158/1538-7445.am2016-2654
https://doi.org/10.1158/1538-7445.am2016-2654
